Evolus Inc (EOLS) Stock Price, Quote & News

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 949 284 4555

Website: www.evolus.com

Address:

520 Newport Center Drive, Suite 1200, Newport Beach, United States

DCRMIA Aug. 21 at 9:40 AM

$EOLS "Mizuho Reiterates Outperform Rating on Evolus" https://www.investing.com/news/pro/mizuho-maintains-evolus-at-outperform-with-a-price-target-of-1900-4203836

0 · Reply

Damian23 Aug. 20 at 4:56 PM

$EOLS Q2 2025 revenue: $69.4 million; 2025 guidance: $295–$305 million. Current market cap: $461 million (updated). Debt: $154.5 million; Cash: $61.7 million. Shares outstanding: 64 million. Enterprise Value (EV) = Market Cap + Debt - Cash = 461M + 154.5M - 61.7M = $553.8 million. EV / 2025 revenue midpoint ($300M) = 553.8M / 300M = ~1.85x. Assume conservative 20% annual revenue growth after 2025. Projected revenue 2026 = $295M × 1.2 = $354 million. Projected revenue 2027 = $354M × 1.2 = $425 million. Using EV/Revenue multiple of 1.85x for 2027 (conservative): EV 2027 = $425M × 1.85 = $786 million. Equity value 2027 = EV - Debt + Cash = 786M - 154.5M + 61.7M = $693 million. Fair value per share = $693M / 64M = $10.8 per share. Current price ~$7.20 (based on market cap and shares) vs. fair value $10.8. Upside potential under conservative assumptions is about 50%.

0 · Reply

prismmarketview Aug. 20 at 2:18 PM

(NASDAQ: $EOLS) @Evolus has submitted its PMA application to the FDA for Evolysse™ Sculpt, its flagship injectable HA gel targeting mid-face volume restoration. Backed by strong pivotal trial data, Sculpt leverages innovative Cold-X™ technology and is expected to enter the highest-value dermal filler segment, with FDA approval anticipated in 2H 2026. This milestone expands Evolus’ portfolio and positions the company for continued growth in aesthetics. https://prismmarketview.com/evolus-submits-fda-premarket-approval-application-for-evolysse-sculpt-injectable-ha-gel/

0 · Reply

Allf2 Aug. 20 at 11:29 AM

$EOLS It's still cheap

0 · Reply

adaptnow Aug. 17 at 10:05 PM

$EOLS @Bilbo9494 could you please explain your reasoning as to why Club Evolus was a bad idea? Perhaps it would be perceived as a win for Evolus, but a loss for the practice? It would certainly be a win for the consumer. Evolus’ primary customer is the aesthetics practice, so if it was perceived as a loss for the practice, the whole strategy becomes a non-starter. Their primary customer decides not to promote Club Evolus. On the other hand, having a patient come back every 3 months means an appointment (aka opportunity to sell additional services), but if there is no willingness to spend more than the minimum Jeuveau treatment, it’s a loss leader that doesn’t translate into upside. If Evolus had a subscription base it might even out some of the lumpiness in cyclical quarterly sales revenue. So from that perspective, I understand their motivation to pursue this path.

0 · Reply

lknite Aug. 14 at 11:47 PM

$EOLS i like that 6.67, noice

0 · Reply

Estimize Aug. 13 at 8:00 PM

Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c

0 · Reply

Allf2 Aug. 13 at 2:17 PM

$EOLS It's a little loaded

0 · Reply

lknite Aug. 13 at 2:40 AM

$EOLS i'll sell you my shares for 11.95, see ya after awhile

0 · Reply

lknite Aug. 13 at 12:47 AM

$EOLS yay!

0 · Reply

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 8, 2025, 4:05 PM EDT - 12 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 5, 2025, 7:15 PM EDT - 15 days ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 15 days ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:05 AM EDT - 20 days ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 22, 2025, 8:05 AM EDT - 4 weeks ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 21, 2025, 5:20 PM EDT - 4 weeks ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jun 10, 2025, 8:00 AM EDT - 2 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards

May 27, 2025, 4:15 PM EDT - 3 months ago

Evolus Announces Departure of its Chief Financial Officer

May 22, 2025, 8:00 AM EDT - 3 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 7, 2025, 7:13 PM EDT - 3 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Evolus Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 3 months ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Apr 23, 2025, 8:00 AM EDT - 4 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 16, 2025, 8:00 AM EDT - 4 months ago

Evolus Announces Commercial Launch of Evolysse™

Apr 15, 2025, 8:00 AM EDT - 4 months ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 4, 2025, 11:18 PM EST - 6 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:17 PM EST - 6 months ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:05 PM EST - 6 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Feb 27, 2025, 8:00 AM EST - 6 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 6 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 18, 2025, 8:00 AM EST - 6 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 13, 2025, 1:45 PM EST - 6 months ago

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:30 PM EST - 6 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Jan 21, 2025, 8:00 AM EST - 7 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 14, 2025, 2:00 PM EST - 7 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Nov 6, 2024, 7:28 PM EST - 10 months ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 4:05 PM EST - 10 months ago

Evolus Reports Third Quarter 2024 Results

Nov 1, 2024, 8:00 AM EDT - 10 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Oct 31, 2024, 2:02 PM EDT - 10 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 23, 2024, 8:00 AM EDT - 10 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:09 PM EDT - 1 year ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

May 22, 2024, 7:00 AM EDT - 1 year ago

Evolus: Chiseling Away At The Aesthetic Market

May 20, 2024, 8:30 AM EDT - 1 year ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 15, 2024, 8:30 AM EDT - 1 year ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

May 10, 2024, 9:10 AM EDT - 1 year ago

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

May 7, 2024, 11:27 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

DCRMIA Aug. 21 at 9:40 AM

$EOLS "Mizuho Reiterates Outperform Rating on Evolus" https://www.investing.com/news/pro/mizuho-maintains-evolus-at-outperform-with-a-price-target-of-1900-4203836

0 · Reply

Damian23 Aug. 20 at 4:56 PM

0 · Reply

prismmarketview Aug. 20 at 2:18 PM

0 · Reply

Allf2 Aug. 20 at 11:29 AM

$EOLS It's still cheap

0 · Reply

adaptnow Aug. 17 at 10:05 PM

0 · Reply

lknite Aug. 14 at 11:47 PM

$EOLS i like that 6.67, noice

0 · Reply

Estimize Aug. 13 at 8:00 PM

Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c

0 · Reply

Allf2 Aug. 13 at 2:17 PM

$EOLS It's a little loaded

0 · Reply

lknite Aug. 13 at 2:40 AM

$EOLS i'll sell you my shares for 11.95, see ya after awhile

0 · Reply

lknite Aug. 13 at 12:47 AM

$EOLS yay!

0 · Reply

Premier24 Aug. 12 at 7:11 PM

$EOLS why the move?

0 · Reply

forgottenchuck Aug. 11 at 6:20 PM

$EOLS what the foook happen to this company, they going bankrupt?

0 · Reply

Luckyluck39 Aug. 11 at 5:15 PM

$EOLS easy 3-4 USD

0 · Reply

showtiime Aug. 11 at 1:41 PM

$EOLS Swing trade

0 · Reply

adaptnow Aug. 10 at 1:18 AM

$EOLS what ever happened to Club Evolus? If the consumer is tightening up, $150 for treatment every 3 months ($49 per month) is still way cheaper than even a single treatment every 6 months. No mention makes me wonder if it’s completely off the radar? Also, they ran some deep discount promos at beginning of the quarter for Jeuveau 6 year anniversary, one with a 72 hour window. Probably pulled forward some purchases that might have come later in the quarter with higher volume vial counts. Letybo is also aggressive with their neurotoxin sampling and prices. Beneev is a fierce competitor (Letybo, exosomes, RF devices) so they have large distribution channel and products to bundle. Similar to Prolennium (HA filler from Canada) they don’t hold back on discounts to gain market share. Investors should have know when Evolus started sponsoring In-N-Out Day at Coachella they are losing sight of fiscal discipline. To go from CMO fluff to no CMO and no CFO seems like full retreat mode.

1 · Reply

BioGem Aug. 9 at 3:02 PM

$EOLS Took a short in the low 6's, many critical issues: -Big revenue guidance downgrade. -Big misses on top and bottom lines. -Eroding gross margin and all other margins. -Insane cash burn, the most in more than 2 years. -Current liabilities are rapidly increasing = more cash burn coming and essentially minimal cash will remain. -Negative book value and stockholder equity. -Insiders always sell stock throughout the year. -Have no CFO and CMO. -Dilution and ATM on ongoing. -High short interest and downgrades by analysts.

3 · Reply

Allf2 Aug. 8 at 8:56 PM

$EOLS oversold zone,starting to load a bit

1 · Reply

lknite Aug. 8 at 4:15 PM

$EOLS i listened to their earnings, and ok ya, so they made less money than expected, but they still made millions and millions ... so much money; seems silly the price would drop, but makes sense, this is how you get a good entry ... its not like they are suddenly going to go out of business; am i missing something?

2 · Reply

hyodong Aug. 8 at 3:45 PM

$EOLS burning through cash. Yikes.

1 · Reply

lknite Aug. 8 at 3:18 PM

$EOLS i'm in at 5.95, looks like a good entry

0 · Reply

Tyranic Aug. 7 at 12:16 AM

$EOLS Back in at 4.50

0 · Reply

galaxySky Aug. 6 at 8:10 PM

$EOLS with $TARS and $IONQ this is in good company. Everyone is dealing with the storm. I wonder if Wall Street will adjust its tune here.

0 · Reply

Market Cap	461.20M
Revenue (ttm)	266.27M
Net Income (ttm)	-50.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.94%
Debt to Equity Ratio	-7.80

Volume	1,122,700
Avg Vol	1,474,208
Day's Range	N/A - N/A
Shares Out	64.69M
Stochastic %K	97%
Beta	1.12
Analysts	Strong Sell
Price Target	$19.83